Navigation Links
Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
Date:7/31/2013

HUNTSVILLE, Ala., July 31, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has entered into a research agreement with the Scripps Research Institute for development of polymer-antibody drug conjugates (Polymer-ADCs). The nature of the agreement and the financial terms were not disclosed.

"Antibody drug conjugates represent one of the most exciting areas of drug development in oncology," according to Dr. Randall Moreadith, President and Chief Executive Officer of Serina Therapeutics, Inc. "The ability to target antibodies that are "pay-loaded" with a potent cytotoxic agent has started to produce the first generation of approved antibody drug conjugates. Our polymer technology platform is uniquely suited to advance this field. We are very excited about working with some of the premier antibody scientists in the world at the Scripps Research Institute to develop next-generation ADCs."

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

About Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, TSRI has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where it's renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

CONTACT: Randall Moreadith, 256-327-0470, rmoreadith@serinatherapeutics.com


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
2. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
3. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
4. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
5. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
6. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
7. Frost & Sullivan: Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
8. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
9. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
10. Cell Therapeutics to Report Second Quarter Financial Results after Market on July 31, 2013
11. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... , Sept. 5, 2017  Xyntek Inc. has announced another milestone in their ... Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams ... ... engagements regionally. ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... , ... Japanese Zen artist couple, Fumie and Kentaro Mune, have announced to ... at Miranda Kuo Gallery on Lower East Side, NYC. This exhibition will feature some ... Wanderlust , one of the largest US yoga online media outlets in the world, ...
(Date:9/21/2017)... ... 2017 , ... FlipBelt, the fitness brand that specializes in problem solving fitness ... market with the launch of their FlipBelt Crops. , The new fitness bottoms feature ... fingertips while at the gym, on the trail, or on-the-go. , “We always thought ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... offices serving communities in northern Alabama and Georgia, is embarking on an extended ... by utilizing modern early detection methods. , US Breast Cancer statistics show ...
(Date:9/20/2017)... ... 20, 2017 , ... Reflections Recovery Center, a men-only drug ... Joint Commission for chemical dependency and behavioral health services. , The Joint Commission ... that meet the commission’s rigorous standards. Accreditation by The Joint Commission is the ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Plus Coating System for clients that rely on safety and cleanliness. This unique ... microorganisms. , Silver has been used for centuries for its antimicrobial properties. Unlike ...
Breaking Medicine News(10 mins):